Future of personalized pharmacotherapy in chronic heart failure patients

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Heart failure (HF) patient populations exhibit significant diversity.
• Current HF treatment guidelines often fail to account for individual response variations.
• Standard treatment protocols derived from limited demographics are broadly applied to diverse groups, including women and African-Americans.

Purpose of the Study:

• To highlight the need for personalized heart failure pharmacotherapy.
• To introduce pharmacogenetics as a strategy for tailoring HF treatment.
• To emphasize the role of genetic biomarkers in predicting treatment response and toxicity.

Main Methods:

• Review of subgroup analyses from randomized HF trials.
• Analysis of retrospective cohort studies on HF treatment customization.
• Exploration of emerging pharmacogenetic approaches in HF management.

Main Results:

• Existing HF treatment strategies lack personalization for diverse patient groups.
• Subgroup analyses and cohort studies provide some basis for customizing regimens.
• Pharmacogenetics presents a promising avenue for predicting individual treatment outcomes.

Conclusions:

• Personalized HF management is essential to maximize therapeutic benefits.
• Genetic biomarkers hold potential for predicting patient response and toxicity.
• Further research is needed to fully integrate pharmacogenetics into clinical HF practice to limit adverse events.